RxDoctor Payments Data

Erin Kleismit

Acute Care · Silver City, NMNPI 1346645744

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $324 and has fallen 52.6% since, to $154 in 2024.

$706in general payments, 2019–2025

Across 37 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$134
  • AstraZeneca$126
  • Abbott$100
  • Cvrx, Inc.$59
  • Novartis$58
  • E.r. Squibb & Sons, L.L.C.$47
  • plus $182 from 7 others

What the payments were for

  • Food & beverage$706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$706 in reported general payments places this provider in the 65th percentile of 132 acute care providers in New Mexico.

See all acute care providers in New Mexico

Medicare billing

Part B allowed, 2024
$87,791
Medicare patients
429
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban264$300,700
XareltoRivaroxaban78$83,194
EntrestoSacubitril/Valsartan37$63,367
Metoprolol Succinate231$2,983
Flecainide Acetate57$2,358
Diltiazem 24hr Er (Cd)Diltiazem Hcl41$1,532
Atorvastatin Calcium149$1,183
Losartan Potassium107$1,164
Lisinopril152$1,150
Metoprolol Tartrate77$1,125
Amlodipine Besylate119$1,034
Rosuvastatin Calcium73$705
Carvedilol102$696
Diltiazem 24hr ErDiltiazem Hcl17$626
Omega-3 Acid Ethyl Esters12$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$58$63,36737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 132 acute care providers in New Mexico.

Other acute care in Silver City

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →